Back to Authors

Habtemarian, Bahru A.

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 1

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis
Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Frishberg, Yaacov, Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Habtemarian, Bahru A., Bhan, Ishir , McGregor, Tracy L., Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B2-B2

10.1681/asn.20213210s1b2a Get It